The role of β-blockers in chronic heart failure <br /> <br />
Journal Title: Αρχεία Ελληνικής Ιατρικής - Year 2003, Vol 20, Issue 1
Abstract
Until recently β-blockers were contraindicated for the treatment of chronic heart failure and their administration was avoided in heart failure patients. The use of β-blockers in heart failure is justified by the fact that increased activation of the adrenergic system in heart failure results in adverse biological signals to the cardiac myocytes. While the effects of β-blockers on exercise capacity and quality of life in heart failure patients are still controversial, clinical trials clearly show improvement in left ventricular function and reduction in its size, as well as fewer hospitalizations from aggravated heart failure. Four adequately powered β-blocker trials, US Carvedilol, CIBIS II, MERIT-HF and COPERNICUS, showed that treatment with β-blockers significantly reduced total and sudden death mortality in heart failure patients. Now, β-blockers are recommended for patients with mild to severe chronic heart failure (NYHA functional class II–IV) and with depressed left ventricular function. Uncertainties still persist about the use of β-blockers in patients with NYHA functional class I and in some specific patient groups with heart failure. Treatment with β-blockers should be started at a very low initial dosage and then titrated up to the maximal tolerated dosage. Today, despite impressive results in terms of morbidity and mortality, β-blocker use in heart failure patients is limited, with only a minority of them benefitting.
Authors and Affiliations
P. GEORGAKOPOULOS, M. KYRIAKIDIS
Keywords
Related Articles
- EP ID EP112906
- DOI -
- Views 116
- Downloads 0
QTc prolongation in psychiatric inpatients: A cross-sectional study
OBJECTIVE Antipsychotic drugs (AD) are prescribed frequently and they often cause serious cardiovascular side effects, especially QTc prolongation. QTc prolongation and dispersion can predict drug induced arrhythmias and...
Αplastic anemia in children: Pathogenetic mechanisms and current therapy
Aplastic anemia (AA) is a severe, acquired hematological disease, which is usually idiopathic. There are two peaks of incidence, at 15–25 years and above 60 years. In children under the age of 15 years, there are 1–3 cas...
Uninfected para-anastomotic aortic aneurysm after infrarenal aortic grafting
No abstract available
Bowel wall hematoma
No abstract available
Clinical findings of thyroid cancer in 288 Japanese Early soft tissue and bone metastases with raised serum thyroglobulin (Tg) in follicular and undifferentiated types
OBJECTIVE Investigation of the clinical findings in 661 Japanese patients with thyroid nodules, of which 288 (44%) were malignant. METHOD AND RESULTS Of the 288 malignant thyroid nodules, histological examination show...